Welcome to our dedicated page for Glucotrack SEC filings (Ticker: GCTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skimming a 300-page medical-device filing to locate FDA trial milestones or cash-burn data is tedious. Glucotrack’s disclosures are packed with sensor-accuracy tables, clinical timelines and intricate revenue projections—details vital to anyone following non-invasive glucose monitoring. If you have ever wondered, “Where do I find Glucotrack SEC filings explained simply?” this page is built for you.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K and Form 4 the moment it hits EDGAR. Need the Glucotrack quarterly earnings report 10-Q filing distilled to the R&D line and unit-economics? Our engine generates an at-a-glance brief. Trying to track Glucotrack insider trading Form 4 transactions or set alerts for Glucotrack Form 4 insider transactions real-time? We surface each executive stock move alongside context. Even dense corporate actions get clarity—see Glucotrack 8-K material events explained within minutes of submission.
What can you uncover here?
- Glucotrack annual report 10-K simplified—AI highlights clinical-trial spend, device-approval risk factors and segment revenue.
- Glucotrack proxy statement executive compensation—quick grids linking pay to CBGM milestones.
- Glucotrack earnings report filing analysis—auto-generated visuals on quarter-over-quarter cash burn.
- understanding Glucotrack SEC documents with AI—plain-language summaries plus direct page references.
- Glucotrack executive stock transactions Form 4—pattern recognition on buys vs. sells before trial readouts.
Whether you monitor regulatory catalysts, compare sensor-accuracy metrics, or simply want confirmation that management’s incentives align with shareholders, our real-time feed and expert commentary turn raw filings into actionable knowledge—no biomedical jargon required.
GlucoTrack, Inc. (GCTK) 10-Q highlights key liquidity, capital-raising and equity-structure actions through June 30, 2025. The company reported cash and cash equivalents of $9,555 and continued operating losses, with multiple periods showing losses (examples include $11,589, $7,416, $4,756, $4,489 reflected across periods). Share count rose materially to 899,410 shares outstanding as of June 30, 2025 from 13,409 at 12/31/2024 following public offerings, private placements and warrant exchanges.
The company completed a February 2025 1-for-20 reverse split and a June 2025 1-for-60 reverse split, and stockholders approved increasing authorized common shares from 100,000,000 to 250,000,000. Financing activity included at-the-market sales and registered offerings generating net proceeds such as $4,320, $3,643, and a private placement raising approximately $500. Derivative warrant liabilities changed, with a June 30, 2025 reported balance movement (fair value adjustments noted). Management states it plans to finance operations via equity or debt and notes there is no assurance of obtaining sufficient financing to continue as a going concern.
GlucoTrack (NASDAQ:GCTK) filed an 8-K announcing the issuance of a press release on June 25, 2025. However, the actual content of the press release is not included in this filing. The 8-K serves only as a notice under Regulation FD that a press release was issued and is being furnished as Exhibit 99.1. The filing was signed by Paul Goode, Chief Executive Officer.
The actual material information or substance of the press release cannot be analyzed as it is not provided in this filing.FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
